2015 Review of Vogelstein “Bad Luck” Cancer & Stem Cell Paper in Science January 02, 2015 2014 What Does New Paper Mean for Future of Nuclear Transfer ES Cells? November 9, 2014 Encouraging New Paper on ACT Stem Cell-Based Trial for Macular Degeneration October 14, 2014 Top 10 Takeaways From Harvard Stem Cell Diabetes […]
Post-Publication Paper Reviews & Commentaries Read More »
The Niche is the top, most authoritative stem cell and regenerative medicine blog on the web and the only one to our knowledge written by a professor. It is mainly written by Professor Paul Knoepfler of UC Davis School of Medicine, an internationally respected stem cell biologist and educator. Knoepfler is an advocate of rigorous
About Us, The Niche and Knoepfler Lab Read More »
I invited Nobel Laureate Shinya Yamanaka to do an interview on the future of clinical translation of induced pluripotent stem cells (iPSC). He provides some intriguing new insights into the iPSC field and the broader stem cell arena. PK: The Takahashi Team’s active Clinical Study using iPSCs to make RPEs to treat Macular Degeneration has
Shinya Yamanaka Interview on Clinical Use of IPSC Read More »
Before the two STAP cell papers were published in Nature in January of 2014, much of the same data was reportedly submitted as single papers to other high-profile journals including Science. In these cases, the proto-STAP papers as we might call them were rejected. But why? Until now we largely could only speculate. However, the reviews
Full Reviews of Rejected STAP Paper Point to Early Signs of Big Trouble Read More »
Many of this The Niche‘s readers ask about what my own lab’s research. What is the focus of the research of the Knoepfler Lab? You can go check out our lab website, but I thought it might be time to blog about what we are all about as a lab and what we have been
Knoepfler Lab: Our mission and research Read More »
Parabiosis and aging When it comes to anti-aging science, creepy meets cool with “young blood” in new blood mixing studies just published. The researchers report that blood from young animals literally makes older animals younger. That striking claim is made by both of two independent teams. They published high-profile papers that just came
Parabiosis and young blood anti-aging in mice Read More »
Today’s post is an interview I did with Dr. Van Bokkelen covering 10 questions. Dr. Gil Van Bokkelen is Chairman and CEO of Athersys, Inc., a company that has focused heavily on stem cells and regenerative medicine for more than a decade. For more on Dr. Van Bokkelen’s background see additional bio section at the end of
Interview with Gil Van Bokkelen Read More »
Back-to-back papers (here and here) in Nature Biotechnology report the transdifferentiation (now often simply referred to as “direct reprogramming”) of plain old fibroblasts into brain cells called oligodendrocyte progenitor cells (OPCs). OPCs are a remarkably useful kind of brain cell that generates myelin, which insulates nerves. OPCs are thought to have great therapeutic potential for
Please support the Roman Reed Spinal Cord Injury Research Act. It’s in Jerry Brown’s hands now. This will take 1 minute of your time and make a world of difference. How to get in touch? You may contact Governor Jerry Brown by mail at: Governor Jerry Brown, c/o State Capitol, Suite 1173, Sacramento, CA 95814 Phone: (916)
Please tell Guv Jerry Brown to sign the Roman Reed Spinal Cord Injury Research Act Read More »
Medulloblastoma is the most common pediatric brain tumor. However, treatments for children who are diagnosed with so-called medullos have not evolved much over the years and are largely similar to treatments given to adults for other brain tumors. One frequent event in certain medullos is amplification of two members of the MYC family of oncogenes
New medulloblastoma paper suggests novel avenues to treat this childhood cancer Read More »